poster

Bioequivalence of Once-Daily Extended-Release Lorazepam Compared to Twice-Daily Immediate-Release Lorazepam

Abstract: Lorazepam is an allosteric GABA-receptor modulator approved for the treatment of anxiety. The existing formulation delivers immediate-release lorazepam to provide short-term anx...

01/19/2023

Bioequivalence of Once-Daily Extended-Release Lorazepam Compared to Thrice-Daily Immediate-Release Lorazepam

Abstract: Lorazepam is an allosteric GABA-receptor modulator approved for the treatment of anxiety and primarily administered as immediate-release tablets. The current immediate-release f...

01/19/2023

Mindfulness-based teacher training: Everyday Mindfulness for Schools (EMS) – A pilot study using mixed method approach

Abstract: Statistics have shown over time that teaching is one of the most stressful occupations.Recently, mindfulness training (MT) has emerged as a useful and tested means to support ed...

01/19/2023

Symptom Tracking using TempusPRO in Patients with Pharmacogenetic Testing From a Real-World Dataset

Abstract: Background Patients with neuropsychiatric illness have inconsistent responses to medications. Pharmacogenomic testing (PGx) helps identify patients who may better respond to ce...

01/19/2023

Effect of Lemborexant Treatment in Older Adults with Insomnia and Objective Short Sleep Duration as Assessed by Polysomnographic Sleep Measures

Abstract: Introduction: There is evidence that insomnia patients with objective short-sleep duration (I-SSD; total sleep time [TST]

01/19/2023

Subjects with Insomnia Disorder and Comorbid Pain at Baseline: Response to Lemborexant

Abstract: Introduction: There is a well-established reciprocal relationship between pain and poor sleep. Therefore, it is clinically important to evaluate whether a sleep-promoting drug s...

01/19/2023

Esketamine is Safe and Effective for Treatment-Resistant Depression in a Real-World Outpatient Setting

Abstract: Approximately one third of major depression cases will not remit even with two or more medication trials, defined as treatment-resistant depression (TRD). The newest FDA-approve...

01/19/2023

Dosing and Reasons for Transitioning From Sodium Oxybate to Lower-Sodium Oxybate: Data From the Transition Experience of Patients With Narcolepsy Taking Oxybate in the Real-World (TENOR) Study

Abstract: Introduction: The TENOR study examines the impact of transitioning from sodium oxybate (SXB) to lower-sodium oxybate (LXB; 92% less sodium than SXB) in a real-world setting. Met...

01/19/2023

Efficacy of Lower-Sodium Oxybate in Participants With Idiopathic Hypersomnia: Results From the Open-label Treatment Phase of a Clinical Study

Abstract: Introduction: Idiopathic hypersomnia is characterized by excessive daytime sleepiness, sleep inertia, and in some patients, long sleep time; these symptoms may partially overlap...

01/19/2023

Qualitative Case Study: Implementation of Patient Reported Outcome Monitoring in a Mental Health Practice to Enhance Care and Improve Business

Abstract: Background: We present a case study to demonstrate how patient-reported outcomes (PROs) are used in mental health, and their impact on patient health and engagement. Methods: I...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products